Drugs.com - New Drug Approvals

FDA Approves Xbryk (denosumab-dssb), a Biosimilar to Xgeva

INCHEON, Korea – Feb 16, 2025 – Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Xbryk (denosumab-dssb; SB16; 120 mg vial), a biosimilar...

Feb 17, 2025 - 22:33
 0
FDA Approves Xbryk (denosumab-dssb), a Biosimilar to Xgeva
INCHEON, Korea – Feb 16, 2025 – Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Xbryk (denosumab-dssb; SB16; 120 mg vial), a biosimilar...
Read More

Tags:

Previous Article

A Nifty Device Could One Day Turn Your Car’s Exhaust Into Electricity

Next Article

STAT+: STAT is backing up and monitoring CDC data in real time: See what’s changing

Related Posts

FDA Approves Vimkunya (chikungunya vaccine, recombinant) for Prevention of Disease Caused by Chikungunya Virus

FDA Approves Vimkunya (chikungunya vaccine, recombinant...

Feb 17, 2025  0

FDA Approves Romvimza (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor

FDA Approves Romvimza (vimseltinib) for the Treatment o...

Feb 17, 2025  0

Uplizna (inebilizumab-cdon) is Now the First and Only FDA-Approved Treatment for IgG4-Related Disease

Uplizna (inebilizumab-cdon) is Now the First and Only F...

Apr 14, 2025  0